Patient | Age | Sex | Cancer type | Cancer stage | ICI | Best overall response to ICI | IRAEs, except MS |
1 | 78 | Male | Melanoma | IV | Nivolumab | Partial response | Vitiligo, itching |
2 | 37 | Male | Melanoma | III | Pembrolizumab (adjuvant) | No evidence of disease | Colitis |
3 | 75 | Female | Melanoma (uvea) | IV | Nivolumab | Partial response | Suspected colitis, vertigo |
4 | 72 | Female | melanoma | IV | Nivolumab/ ipilimumab* | Partial response | Vitiligo |
5 | 73 | Male | melanoma | IV | Nivolumab/ ipilimumab* | Partial response | Pneumonitis, conjunctivitis |
6 | 79 | Female | melanoma (uvea) | IV | Nivolumab/ Ipilimumab* | Stable disease | None |
7 | 49 | Male | melanoma | IV | Nivolumab | Progress | Suspected pneumonitis, pancreatitis |
8 | 51 | Male | NSCLC | IIIb | Nivolumab | Progress | None |
9 | 65 | Male | melanoma (uvea) | IV | Ipilimumab/pembrolizumab | Stable disease | Pruritus, pancreatitis |
10 | 53 | Female | melanoma | IV | Pembrolizumab | Partial response | None |
11 | 73 | Male | Melanoma | IV | Pembrolizumab | Partial response | Colitis, myasthenic symptoms |
12 | 58 | Female | NSCLC | IIIb | Nivolumab | Stable disease | None |
13 | 60 | Male | NSCLC | IIIb | Nivolumab | Stable disease | None |
14 | 65 | Male | NSCLC | IIIa | Nivolumab | Stable disease | None |
*Combination therapy.
Age, refers to age at first onset of musculoskeletal IRAEs; ICI, immune checkpoint inhibitor; IRAEs, immune-related adverse events; MS, musculoskeletal; NSCLC, non-small cell lung cancer.